Omkar Pharmachem Ltd
Omkar Pharmachem Ltd (OMKARPH) last reported results for the quarter ended Jun 2026, with sales of ₹0.09 crore and net profit of ₹-0.01 crore. The stock last traded at ₹10.2, a market capitalisation of ₹10.3 crore, on a P/E of 114. Over the past 52 weeks the stock has ranged between ₹7.08 and ₹29.7. Figures are as of 6 Oct 2026 and are not real time.
Omkar Pharmachem Ltd share price and key metrics
- Current price
- ₹10.2
- Market cap
- ₹10.3 cr
- Stock P/E
- 114
- Book value
- ₹36.3
- ROE
- 0.52%
- ROCE
- 0.74%
- Dividend yield
- 0.00%
- 52w high / low
- 29.7/7.08
Metrics as of 6 Oct 2026. Not real time.
Track Omkar Pharmachem Ltd
Cruxal reads every Omkar Pharmachem Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Omkar Pharmachem Ltd growth and returns
- 10 Years
- %
- 5 Years
- 12%
- 3 Years
- -5%
- TTM
- -23%
- 10 Years
- 12%
- 5 Years
- -11%
- 3 Years
- -16%
- TTM
- -50%
- 10 Years
- %
- 5 Years
- -12%
- 3 Years
- -21%
- 1 Year
- -62%
- 10 Years
- 0%
- 5 Years
- 2%
- 3 Years
- 1%
- Last Year
- 1%
Omkar Pharmachem Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.09 cr, down 35.7% from ₹0.14 cr a year earlier. Net profit swung to a loss of ₹0.01 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.11 | 0.09 | 0.09 |
| Expenses | 0.05 | 0.05 | 0.07 | 0.1 | 0.07 | 0.07 | 0.07 | 0.1 |
| Operating profit | 0.09 | 0.09 | 0.07 | 0.04 | 0.07 | 0.04 | 0.02 | -0.01 |
| OPM % | 64.29% | 64.29% | 50.00% | 28.57% | 50.00% | 36.36% | 22.22% | -11.11% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0.02 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0.09 | 0.09 | 0.05 | 0.04 | 0.07 | 0.04 | 0.02 | -0.01 |
| Tax % | 0.00% | 0.00% | 140.00% | 25.00% | 28.57% | 25.00% | 0.00% | 0.00% |
| Net profit | 0.09 | 0.08 | -0.02 | 0.03 | 0.05 | 0.03 | 0.02 | -0.01 |
| EPS (₹) | 0.09 | 0.08 | -0.02 | 0.03 | 0.05 | 0.03 | 0.02 | -0.01 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Omkar Pharmachem Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0.05 | 0.27 | 0.54 | 0.54 | 0.54 | 0.54 | 0.47 | 0.43 |
| Operating profit | -0.22 | -0.24 | -0.38 | -0.21 | 0.03 | 0.27 | 0.32 | 0.29 | 0.3 | 0.16 | 0.12 |
| OPM % | — | — | — | -420.00% | 11.11% | 50.00% | 59.26% | 53.70% | 55.56% | 34.04% | 27.91% |
| Net profit | 0.22 | -0.26 | -0.42 | -0.26 | 0.22 | 0.18 | 0.2 | 0.19 | 0.2 | 0.12 | 0.09 |
| EPS (₹) | 0.22 | -0.26 | -0.42 | -0.26 | 0.22 | 0.18 | 0.20 | 0.19 | 0.20 | 0.12 | 0.09 |
TTM is the trailing twelve months to the most recent quarter.
Omkar Pharmachem Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 |
| Reserves | -0.71 | -0.96 | -1.38 | -1.64 | -1.42 | -1.24 | -1.04 | -0.85 | -0.65 | 26.56 |
| Borrowings | 0.00 | 0.24 | 0.58 | 0.87 | 0.90 | 0.93 | 0.62 | 0.30 | 0.12 | 0.00 |
| Other liabilities | 0.06 | 0.04 | 0.05 | 0.06 | 0.08 | 0.06 | 0.07 | 0.07 | 0.05 | 0.05 |
| Total liabilities | 9.43 | 9.40 | 9.33 | 9.37 | 9.64 | 9.83 | 9.73 | 9.60 | 9.60 | 36.69 |
| Fixed assets | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 36.38 |
| Other assets | 0.13 | 0.09 | 0.03 | 0.07 | 0.34 | 0.52 | 0.43 | 0.29 | 0.29 | 0.31 |
| Total assets | 9.43 | 9.40 | 9.33 | 9.37 | 9.64 | 9.83 | 9.73 | 9.60 | 9.60 | 36.69 |
As reported by the company. Total assets equal total liabilities by construction.
Omkar Pharmachem Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0.77 | -0.25 | -0.30 | -0.21 | 0.02 | 0.20 | 0.28 | 0.30 | 0.24 | 0.23 |
| Cash from investing | 0.49 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 |
| Cash from financing | 0.01 | 0.23 | 0.30 | 0.24 | -0.02 | -0.03 | -0.35 | -0.35 | -0.20 | -0.12 |
| Net cash flow | -0.28 | -0.03 | 0.00 | 0.02 | 0.00 | 0.17 | -0.08 | -0.06 | 0.04 | 0.11 |
| Free cash flow | -0.29 | -0.26 | -0.30 | -0.21 | 0.02 | 0.19 | 0.28 | 0.29 | 0.24 | 0.23 |
| CFO / operating profit | 327% | 104% | 79% | 100% | 67% | 74% | 88% | 103% | 80% | 150% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Omkar Pharmachem Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -2.27% | -2.56% | -4.08% | -2.26% | 0.32% | 2.79% | 3.29% | 3.02% | 3.04% | 0.74% |
| Debtor days | — | — | — | 146.00 | 40.56 | 54.07 | 87.87 | 33.80 | 67.59 | 23.30 |
| Cash conversion cycle | — | — | — | 146.00 | 40.56 | 54.07 | 87.87 | 33.80 | 67.59 | 23.30 |
| Working capital days | — | — | — | -6,570.00 | -1,270.74 | -608.33 | -378.52 | -162.22 | -6.76 | 23.30 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Omkar Pharmachem Ltd shareholding pattern
Promoters held 0.03% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% |
| Public | 99.97% | 99.97% | 99.97% | 99.97% | 99.97% | 99.97% | 99.97% | 99.97% |
| No. of shareholders | 3,608 | 3,609 | 3,611 | 3,619 | 3,618 | 3,618 | 3,617 | 3,669 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Omkar Pharmachem Ltd corporate filings
- Corporate Voting Results of Omkar Pharmachem Limited Indicate Stable Shareholder Support for ResolutionsAGM/EGMmedium impact
Cruxal's analysis: Omkar Pharmachem Limited has conducted its 31st Annual General Meeting on 30th September…
Read the full analysis - Omkar Pharmachem Limited holds AGM; no immediate financial disclosures or strategic updates providedAGM/EGMlow impact
Cruxal's analysis: Omkar Pharmachem Limited conducted its 31st Annual General Meeting on 30 September 2026…
Read the full analysis - Dear Sir, Please find Intimation of Closure of Trading Window.Insider Trading / SASTlow impact
- Omkar Pharmachem Ltd announces newspaper publication regarding physical share transfer and dematerializationCompany Updatelow impact
Cruxal's analysis: The company has issued a newspaper notice regarding a special window for the transfer and…
Read the full analysis - Omkar Pharmachem Ltd announces newspaper publication for 31st Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Omkar Pharmachem Ltd has fulfilled its regulatory obligation under Regulation 47 of SEBI…
Read the full analysis - Omkar Pharmachem Limited announces cut-off date for 31st Annual General Meeting e-votingCorp. Actionlow impact
Cruxal's analysis: Omkar Pharmachem Limited has formally notified the BSE that it has fixed 23rd September…
Read the full analysis - Omkar Pharmachem Limited Announces 31st AGM and Material Related Party Transactions for FY 2026-27Othersmedium impact
Cruxal's analysis: Omkar Pharmachem Limited has released its Annual Report for FY 2025-26, scheduling its…
Read the full analysis - Omkar Pharmachem Limited Announces 31st AGM and Seeks Shareholder Approval for Material Related Party TransactionsAGM/EGMlow impact
Cruxal's analysis: Omkar Pharmachem Limited has issued a notice for its 31st Annual General Meeting…
Read the full analysis - Omkar Pharmachem Limited Announces 31st Annual General Meeting for September 30, 2026Otherslow impact
Cruxal's analysis: Omkar Pharmachem Limited has formally announced that its 31st Annual General Meeting…
Read the full analysis - Omkar Pharmachem Limited Reports Unaudited Financial Results for Quarter Ended 30 June 2026Company Updatelow impact
Cruxal's analysis: Omkar Pharmachem Limited has released its unaudited financial results for the quarter…
Read the full analysis - Omkar Pharmachem reports net loss of 1 lakh INR for Q1 FY27 amid stagnant operational incomeResultlow impact
Cruxal's analysis: Omkar Pharmachem Limited reported a net loss of 1 lakh INR for the quarter ended 30 June…
Read the full analysis - Omkar Pharmachem reports net loss of 1 lakh for Q1 FY27 as operational income declinesBoard Meetinglow impact
Cruxal's analysis: Omkar Pharmachem Limited reported a net loss of 1 lakh for the quarter ended 30 June…
Read the full analysis - Omkar Pharmachem Limited schedules Board Meeting for August 13, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Omkar Pharmachem Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.